Editorial
Copyright ©2006 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Aug 21, 2006; 12(31): 4937-4942
Published online Aug 21, 2006. doi: 10.3748/wjg.v12.i31.4937
Post-transcriptional regulation of vascular endothelial growth factor: Implications for tumor angiogenesis
Peter S Yoo, Abby L Mulkeen, Charles H Cha
Peter S Yoo, Abby L Mulkeen, Charles H Cha, Gastrointestinal Surgery and Surgical Oncology, Yale School of Medicine, New Haven, Connecticut, United States
Author contributions: All authors contributed equally to the work.
Correspondence to: Charles H Cha, MD, Department of Surgery, Yale School of Medicine, 330 Cedar Street, LH 118, New Haven, CT 06520-8062, United States. charles.cha@yale.edu
Telephone: +1-203-7852380 Fax: +1-203-9373845
Received: December 1, 2005
Revised: January 5, 2006
Accepted: January 14, 2006
Published online: August 21, 2006
Abstract

Vascular endothelial growth factor (VEGF) is a potent secreted mitogen critical for physiologic and tumor angiogenesis. Regulation of VEGF occurs at several levels, including transcription, mRNA stabilization, translation, and differential cellular localization of various isoforms. Recent advances in our understanding of post-transcriptional regulation of VEGF include identification of the stabilizing mRNA binding protein, HuR, and the discovery of internal ribosomal entry sites in the 5'UTR of the VEGF mRNA. Monoclonal anti-VEGF antibody was recently approved for use in humans, but suffers from the need for high systemic doses. RNA interference (RNAi) technology is being used in vitro and in animal models with promising results. Here, we review the literature on post-transcriptional regulation of VEGF and describe recent progress in targeting these mechanisms for therapeutic benefit.

Keywords: Vascular endothelial growth factor; Vascular endothelial growth hormone; Post-transcriptional regulation; mRNA stability; HuR; ELAV1; Internal ribosomal entry; IRES; siRNA; RNAi; Bevacizumab